Nobel Prize for novel cancer therapies
4 October 2018
Two of the men responsible for the discovery and development of checkpoint inhibitors, therapies that revolutionised the way metastatic melanoma patients are treated, extending lives and improving quality of life for countless patients, were awarded this year’s Nobel Prize in Physiology or Medicine.
Professor James P. Allison from MD Anderson Cancer Centre, and Professor Tasuku Honjo from Kyoto University were jointly awarded the Nobel Prize for their separate work from the early 1990’s, where they each discovered a different protein that plays a major role in regulating the immune system.
The immune system is a balancing act – it is constantly trying to fight off foreign invaders, like viruses and bacteria, without harming the body – that relies heavily on an intricate system of brakes and accelerators. Sometimes the balance is off, resulting in autoimmune diseases where the immune system attacks the body, or diseases like cancer, where the immune system does not recognise that there is anything amiss.
Both Professor Allison and Professor Honjo discovered molecules that act as a brake in the immune system, halting its action and allowing cancers to grow. In Professor Allison’s research, he showed that blocking the molecule he discovered, CTLA-4, could switch off the brake, allowing the immune system to recognise a tumour and attack it. His work lead to the development of the melanoma fighting drug ipilimumab. Professor Honjo discovered the protein PD-1, and found that blocking it allows the immune system to recognise cancer as an invader and mount an immune response. This led to the manufacture of the immunotherapies nivolumab and pembrolizumab.
Ipilimumab, nivolumab and pembrolizumab are now used extensively to treat metastatic melanoma, working to help patient’s own bodies to recognise and fight the disease. Since these treatments have become available, melanoma patients have a better prognosis than ever before.
The two men will receive their Nobel Prizes at a formal ceremony in Stockholm in December. Five different Nobel Prizes are awarded every year, with the Nobel Prize in Physiology or Medicine given to up to three people who have made outstanding discoveries in the fields of medicine or the life sciences. Previous Nobel laureates include three of the men responsible for the discovery of DNA, and the three men who discovered penicillin.
Photograph: Niklas Elmehed/Twitter:NobelPrize
Australasian Melanoma Conference AMC2021
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Community Fundraising Wrap Up Apr-June 2021
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Patients paying it forward
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
Research boost to improve outcomes for melanoma patients
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Riverina Melanoma Ride
Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina this October, to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Amie St Clair 10th Annual Ball
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Melanoma Clinical Trial to open in Wagga
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
Queen's Birthday Honour for Professor Richard Scolyer
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
Sharing our research on the global stage at 2021 ASCO Annual Meeting
Research from MIA was once again in the spotlight as findings were shared at the virtual ASCO21.
Australian researchers lead world in successful trial of new cancer treatment.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Thank you doesn't seem enough for our melanoma nurses.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
Sharing our knowledge of melanoma on the global stage
As leaders in the field of melanoma, clinicians and researchers from MIA shared their knowledge at the virtual 10th World Congress of Melanoma.
Community Fundraising Wrap Up Jan-Mar 2021
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.
Support for Melanoma March has come from everywhere
We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!
An inspiring WA Melanoma Community Forum
There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form.
Family of 8-year-old with melanoma calls on all Australians to step up to help save lives
The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.
Rethinking skin surveillance for high-risk melanoma patients
New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.
Australia's oldest melanoma survivor steps up to save lives on his 105th birthday
Melanoma research saved Bert's life at 101 and now he wants to give back.
Predicting disease spread in thin melanoma
A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.